Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

Inclusion Criteria: Inclusion Criteria: * Patient diagnosed with macular edema due to RVO (either BRVO or CRVO, non-ischemic) * Retinal thickness ≥ 300 μm by SD-OCT in the central 1 mm macular subfield of the study eye at the Screening visit * BCVA score of 19 to 73 letters (approximately 20/400 to 20/40 Snellen equivalent) in the study eye measured by ETDRS method at Screening * \< 3 months of macular edema duration * Treatment-naive patients (ie, have not previously received any treatment for macular edema secondary to RVO) Exclusion Criteria: * Uncontrolled systemic disease * Presence of/history of any ocular condition other than macular edema that affects visual acuity (eg, cataract, severe macular ischemia, foveal atrophy, age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, prior macular detachment) * Any of the following ≤ 3 months before study entry or anticipated need within the coming 3 months: * Intraocular surgery * Laser photocoagulation * Intraocular injection * Periocular steroid injection * Vitrectomized eye * Aphakic eyes with ruptured posterior lens capsule or presence of an ACIOL, iris or transscleral fixated intraocular lens * History of marked IOP elevation in response to steroid treatment that (a) required IOP-lowering treatment, (b) resulted in a \>10 mm Hg increase in IOP from predose, or (c) resulted in IOP \>25 mm Hg * History of glaucoma or ocular hypertension (IOP \> 21 mm H…